Literature DB >> 11600547

Human pheochromocytomas express orexin receptor type 2 gene and display an in vitro secretory response to orexins A and B.

G Mazzocchi1, L K Malendowicz, F Aragona, P Rebuffat, L Gottardo, G G Nussdorfer.   

Abstract

Orexins A and B are hypothalamic peptides, that act through two receptor subtypes, called OX1-R and OX2-R. OX1-R selectively binds orexin A, whereas OX2-R is nonselective for both orexins. High levels of OX1-R mRNA and low levels of OX2-R mRNA have been previously detected in the human adrenal cortex and medulla. Here we demonstrated by RT-PCR the expression of the OX2-R, but not the OX1-R, gene in 10 benign secreting pheochromocytomas. Both orexins A and B stimulated catecholamine secretion from pheochromocytoma slices; the maximal effective concentration was 10(-8) mol/liter. Orexins A and B (10(-8) mol/liter) increased IP3, but not cAMP production, by tumor slices, and the effect was blocked by the PLC inhibitor U-73122. The catecholamine response to 10(-8) mol/liter orexins A and B was abolished by either U-73122 or the PKC antagonist calphostin C and was unaffected by the adenylate cyclase inhibitor SQ-22536 and the PKA inhibitor H-89. Collectively, these findings suggest that orexins stimulate catecholamine secretion from human pheochromocytomas, acting through OX2-R coupled to the PLC-PKC signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11600547     DOI: 10.1210/jcem.86.10.7929

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Orexin/hypocretin receptor signalling: a functional perspective.

Authors:  C S Leonard; J P Kukkonen
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 2.  Orexin/hypocretin receptor signalling cascades.

Authors:  J P Kukkonen; C S Leonard
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

3.  Biased agonism.

Authors:  Terry Kenakin
Journal:  F1000 Biol Rep       Date:  2009-11-26

4.  Radiosynthesis and evaluation of [11C]EMPA as a potential PET tracer for orexin 2 receptors.

Authors:  Changning Wang; Christian K Moseley; Stephen M Carlin; Colin M Wilson; Ramesh Neelamegam; Jacob M Hooker
Journal:  Bioorg Med Chem Lett       Date:  2013-04-02       Impact factor: 2.823

Review 5.  A review of orexin's unprecedented potential as a novel, highly-specific treatment for various localized and metastatic cancers.

Authors:  Nicole L Graybill; Volkmar Weissig
Journal:  SAGE Open Med       Date:  2017-11-03

Review 6.  The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role.

Authors:  Alain Couvineau; Stéphanie Dayot; Pascal Nicole; Valérie Gratio; Vinciane Rebours; Anne Couvelard; Thierry Voisin
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-27       Impact factor: 5.555

Review 7.  Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions.

Authors:  Alain Couvineau; Thierry Voisin; Pascal Nicole; Valerie Gratio; Anne Blais
Journal:  World J Gastroenterol       Date:  2021-11-28       Impact factor: 5.742

Review 8.  The Orexin receptors: Structural and anti-tumoral properties.

Authors:  Alain Couvineau; Pascal Nicole; Valérie Gratio; Thierry Voisin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-28       Impact factor: 6.055

9.  The in vitro regulation of growth hormone secretion by orexins.

Authors:  Chen Chen; Ruwei Xu
Journal:  Endocrine       Date:  2003-10       Impact factor: 3.925

10.  Orexins protect neuronal cell cultures against hypoxic stress: an involvement of Akt signaling.

Authors:  Paulina Sokołowska; Anna Urbańska; Kaja Biegańska; Waldemar Wagner; Wojciech Ciszewski; Magdalena Namiecińska; Jolanta B Zawilska
Journal:  J Mol Neurosci       Date:  2013-11-19       Impact factor: 3.444

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.